Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 6397Neoplasms 5369Prostatic Neoplasms 2966Carcinoma, Non-Small-Cell Lung 2709Colorectal Neoplasms 2679Lung Neoplasms 2269Multiple Myeloma 1663Lymphoma 1600Neoplasm Metastasis 1554Leukemia, Myeloid, Acute 1540Melanoma 1486Pancreatic Neoplasms 1470Ovarian Neoplasms 1424Leukemia 1389Head and Neck Neoplasms 1284Precursor Cell Lymphoblastic Leukemia-Lymphoma 1283Lymphoma, Non-Hodgkin 1231Colonic Neoplasms 1160Carcinoma, Hepatocellular 1142Stomach Neoplasms 1130Leukemia, Lymphocytic, Chronic, B-Cell 1090Brain Neoplasms 1053Rectal Neoplasms 980Lymphoma, Follicular 979Recurrence 978Uterine Cervical Neoplasms 927Glioblastoma 921Carcinoma, Renal Cell 883Lymphoma, Large B-Cell, Diffuse 854Hodgkin Disease 777

Interventions

danusertib 1cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Metastatic Hormone Refractory Prostate Cancer × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00766324 2014-05-28

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Nerviano Medical Sciences

Phase 2 Completed
118 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00636090 2013-12-04

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Duke University

Completed
35 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡